Clearside Biomedical ( (CLSD) ) has provided an update.
On March 27, 2025, Clearside Biomedical announced its financial results for the fourth quarter and full year 2024, alongside a corporate update. The company reported a decrease in license and other revenue, attributing it to prior year milestone payments, and a net loss increase due to reduced revenue. Clearside highlighted its successful End-of-Phase 2 meeting with the FDA for CLS-AX in wet AMD, and its Asia-Pacific partner’s regulatory progress for ARCATUS® in China. The company also noted multiple collaborations and advancements in its suprachoroidal delivery platform, including Phase 3 plans for diabetic retinopathy and ocular oncology trials, positioning itself for potential pipeline expansion and strategic partnerships.
More about Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company focused on revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). The company utilizes its patented SCS Microinjector® for targeted and compartmentalized delivery of therapies to the macula, retina, or choroid, aiming to preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing a pipeline of small molecule product candidates, including its lead program CLS-AX for neovascular age-related macular degeneration (wet AMD), and has developed XIPERE® for suprachoroidal use, available in the U.S. through a commercial partner.
YTD Price Performance: 6.25%
Average Trading Volume: 213,847
Technical Sentiment Signal: Buy
Current Market Cap: $77.36M
See more insights into CLSD stock on TipRanks’ Stock Analysis page.